Central European journal of urology · 2026
One-month postoperative α-blocker therapy reduces morbidity and increases patients' satisfaction and well-being following water jet aquablation for treating benign prostatic obstruction: a randomized prospective trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perez Dolev, Mamber Ariel, Pasherstnik Michael, Koulikov Dmitry, Natsheh Ala Eddin, Shenfeld Ofer Z, Kafka Ilan Z, Hen Adam, Malinger Andres, Zeldin Avital, Ostrovsky Israel A, Chertin Boris
Аннотация
INTRODUCTION: The study aimed to evaluate whether continuing α-blocker therapy for one month after aquablation improves early clinical outcomes in patients undergoing surgery for benign prostatic obstruction (BPO).
MATERIAL AND METHODS: This prospective, single-center study enrolled 240 consecutive patients with symptomatic BPO who underwent aquablation between 2023 and 2025. Patients were divided into two cohorts: cohort A (n = 120) discontinued BPH medications postoperatively, while cohort B (n = 120) continued α-blocker therapy for one month. Functional, sexual, and safety outcomes were assessed at 3, 6, and 12 months using validated tools (IPSS, QoL, VAS, IIEF, MSHQ-EjD-SF, SF-ICIQ). Statistical analysis was used to compare symptom scores, complication rates, and retreatment frequencies between groups.
RESULTS: Both cohorts experienced significant symptom improvement following aquablation. However, cohort B showed superior early outcomes, including a greater reduction in irritative symptoms (p = 0.014 at 3 months; p = 0.02 at 12 months), lower VAS pain scores, and fewer postoperative complications (22.5% vs 30.8%, p = 0.15), with nonsignificantly lower rates of moderate (Grade II) complications in cohort B. Sexual function remained stable in both groups, with cohort B demonstrating improved ejaculatory function scores at all time points. No increase in adverse events was observed with continued use of α-blockers.
CONCLUSIONS: Short-term continuation of α-blocker therapy following aquablation enhances early postoperative recovery, reduces complications, and improves patient-reported well-being without compromising sexual or functional outcomes. Routine one-month α-blocker therapy is a valuable adjunct in aquablation postoperative care.
MATERIAL AND METHODS: This prospective, single-center study enrolled 240 consecutive patients with symptomatic BPO who underwent aquablation between 2023 and 2025. Patients were divided into two cohorts: cohort A (n = 120) discontinued BPH medications postoperatively, while cohort B (n = 120) continued α-blocker therapy for one month. Functional, sexual, and safety outcomes were assessed at 3, 6, and 12 months using validated tools (IPSS, QoL, VAS, IIEF, MSHQ-EjD-SF, SF-ICIQ). Statistical analysis was used to compare symptom scores, complication rates, and retreatment frequencies between groups.
RESULTS: Both cohorts experienced significant symptom improvement following aquablation. However, cohort B showed superior early outcomes, including a greater reduction in irritative symptoms (p = 0.014 at 3 months; p = 0.02 at 12 months), lower VAS pain scores, and fewer postoperative complications (22.5% vs 30.8%, p = 0.15), with nonsignificantly lower rates of moderate (Grade II) complications in cohort B. Sexual function remained stable in both groups, with cohort B demonstrating improved ejaculatory function scores at all time points. No increase in adverse events was observed with continued use of α-blockers.
CONCLUSIONS: Short-term continuation of α-blocker therapy following aquablation enhances early postoperative recovery, reduces complications, and improves patient-reported well-being without compromising sexual or functional outcomes. Routine one-month α-blocker therapy is a valuable adjunct in aquablation postoperative care.